AAAAAA

   
Results: 1-25 | 26-50 | 51-51
Results: 1-25/51
CELLULAR PROVIRAL HIV TYPE-1 DNA LOAD PERSISTS AFTER LONG-TERM RT-INHIBITOR THERAPY IN HIV TYPE-1 INFECTED PERSONS
Authors: BRUISTEN SM REISS P LOELIGER AE VANSWIETEN P SCHUURMAN R BOUCHER CAB WEVERLING GJ HUISMAN JG
Citation: Sm. Bruisten et al., CELLULAR PROVIRAL HIV TYPE-1 DNA LOAD PERSISTS AFTER LONG-TERM RT-INHIBITOR THERAPY IN HIV TYPE-1 INFECTED PERSONS, AIDS research and human retroviruses, 14(12), 1998, pp. 1053-1058
EARLY RECOVERY OF CD4-LYMPHOCYTES IN CHILDREN ON HIGHLY-ACTIVE ANTIRETROVIRAL THERAPY( T)
Authors: STUART JWTC SLIEKER WAT RIJKERS GT NOEST A BOUCHER CAB SUUR MH DEBOER R GEELEN SPM SCHERPBIER HJ HARTWIG NG HOOIJKAAS H ROOS MT DEGRAEFFMEEDER B DEGROOT R
Citation: Jwtc. Stuart et al., EARLY RECOVERY OF CD4-LYMPHOCYTES IN CHILDREN ON HIGHLY-ACTIVE ANTIRETROVIRAL THERAPY( T), AIDS, 12(16), 1998, pp. 2155-2159
TARGET-CELL AVAILABILITY AND THE SUCCESSFUL SUPPRESSION OF HIV BY HYDROXYUREA AND DIDANOSINE
Authors: DEBOER RJ BOUCHER CAB PERELSON AS
Citation: Rj. Deboer et al., TARGET-CELL AVAILABILITY AND THE SUCCESSFUL SUPPRESSION OF HIV BY HYDROXYUREA AND DIDANOSINE, AIDS, 12(13), 1998, pp. 1567-1570
EFFICIENT INHIBITION OF BOTH SYNCYTIUM-INDUCING AND NON-SYNCYTIUM-INDUCING WILD-TYPE HIV-1 BY LAMIVUDINE IN-VIVO
Authors: WOUT ABVT RAN LJ NIJHUIS M TIJNAGEL JMGH DEGROOT T VANLEEUWEN R BOUCHER CAB SCHUITEMAKER H SCHUURMAN R
Citation: Abvt. Wout et al., EFFICIENT INHIBITION OF BOTH SYNCYTIUM-INDUCING AND NON-SYNCYTIUM-INDUCING WILD-TYPE HIV-1 BY LAMIVUDINE IN-VIVO, AIDS, 12(10), 1998, pp. 1169-1176
SUMMARY OF THE INTERNATIONAL CONSENSUS SYMPOSIUM ON MANAGEMENT OF HIV, CMV AND HEPATITIS-VIRUS INFECTIONS
Authors: DEJONG MD BOUCHER CAB DANNER SA GAZZARD B GRIFFITHS PD KATLAMA C LANGE JMA RICHMAN DD VELLA S
Citation: Md. Dejong et al., SUMMARY OF THE INTERNATIONAL CONSENSUS SYMPOSIUM ON MANAGEMENT OF HIV, CMV AND HEPATITIS-VIRUS INFECTIONS, Antiviral research, 37(1), 1998, pp. 1-16
IN-VIVO ANTI-CD3-INDUCED HIV-1 VIREMIA
Authors: BRINKMAN K HUYSMANS F GALAMA JMD BOUCHER CAB
Citation: K. Brinkman et al., IN-VIVO ANTI-CD3-INDUCED HIV-1 VIREMIA, Lancet, 352(9138), 1998, pp. 1446-1446
STOCHASTIC-PROCESSES STRONGLY INFLUENCE HIV-1 EVOLUTION DURING SUBOPTIMAL PROTEASE-INHIBITOR THERAPY
Authors: NIJHUIS M BOUCHER CAB SCHIPPER P LEITNER T SCHUURMAN R ALBERT J
Citation: M. Nijhuis et al., STOCHASTIC-PROCESSES STRONGLY INFLUENCE HIV-1 EVOLUTION DURING SUBOPTIMAL PROTEASE-INHIBITOR THERAPY, Proceedings of the National Academy of Sciences of the United Statesof America, 95(24), 1998, pp. 14441-14446
ACTIVATION AND CELL-CYCLE ANTIGENS IN CD4(-CELLS CORRELATE WITH PLASMA HUMAN-IMMUNODEFICIENCY-VIRUS (HIV-1) RNA LEVEL IN HIV-1 INFECTION() AND CD8(+) T)
Authors: ORENDI JM BLOEM AC BORLEFFS JCC WIJNHOLDS FJ DEVOS NM NOTTET HSLM VISSER MR SNIPPE H VERHOEF J BOUCHER CAB
Citation: Jm. Orendi et al., ACTIVATION AND CELL-CYCLE ANTIGENS IN CD4(-CELLS CORRELATE WITH PLASMA HUMAN-IMMUNODEFICIENCY-VIRUS (HIV-1) RNA LEVEL IN HIV-1 INFECTION() AND CD8(+) T), The Journal of infectious diseases, 178(5), 1998, pp. 1279-1287
VERTICAL HIV-1 TRANSMISSION CORRELATES WITH A HIGH MATERNAL VIRAL LOAD AT DELIVERY
Authors: COLL O HERNANDEZ M BOUCHER CAB FORTUNY C DETEJADA BM CANET Y CARAGOL I TIJNAGEL J BERTRAN JM ESPANOL T
Citation: O. Coll et al., VERTICAL HIV-1 TRANSMISSION CORRELATES WITH A HIGH MATERNAL VIRAL LOAD AT DELIVERY, Journal of acquired immune deficiency syndromes and human retrovirology, 14(1), 1997, pp. 26-30
HOMOLOGOUS RECOMBINATION FOR RAPID PHENOTYPING OF HIV
Authors: NIJHUIS M SCHUURMAN R BOUCHER CAB
Citation: M. Nijhuis et al., HOMOLOGOUS RECOMBINATION FOR RAPID PHENOTYPING OF HIV, Current opinion in infectious diseases, 10(6), 1997, pp. 475-479
IN-VITRO SELECTION OF HIV-1 VARIANTS RESISTANT TO NONNUCLEOSIDE REVERSE-TRANSCRIPTASE INHIBITORS IN MONOCYTE-DERIVED MACROPHAGES
Authors: BEENTIKTAK AMM DEHAAS CJC DEGRAAF L BOUCHER CAB VERHOEF J BORLEFFS JCC NOTTET HSLM SCHUURMAN R
Citation: Amm. Beentiktak et al., IN-VITRO SELECTION OF HIV-1 VARIANTS RESISTANT TO NONNUCLEOSIDE REVERSE-TRANSCRIPTASE INHIBITORS IN MONOCYTE-DERIVED MACROPHAGES, Journal of antimicrobial chemotherapy, 40(6), 1997, pp. 847-853
CLINICAL-EXPERIENCE WITH NONNUCLEOSIDE REVERSE-TRANSCRIPTASE INHIBITORS
Authors: MILLER V STASZEWSKI S BOUCHER CAB PHAIR JP
Citation: V. Miller et al., CLINICAL-EXPERIENCE WITH NONNUCLEOSIDE REVERSE-TRANSCRIPTASE INHIBITORS, AIDS, 11, 1997, pp. 157-164
OVERSHOOT OF HIV-1 VIREMIA AFTER EARLY DISCONTINUATION OF ANTIRETROVIRAL TREATMENT
Authors: DEJONG MD DEBOER RJ DEWOLF F FOUDRAINE NA BOUCHER CAB GOUDSMIT J LANGE JMA
Citation: Md. Dejong et al., OVERSHOOT OF HIV-1 VIREMIA AFTER EARLY DISCONTINUATION OF ANTIRETROVIRAL TREATMENT, AIDS, 11(11), 1997, pp. 79-84
SUMMARY OF THE 2ND INTERNATIONAL CONSENSUS SYMPOSIUM ON COMBINED ANTIVIRAL THERAPY AND IMPLICATIONS FOR FUTURE THERAPIES
Authors: DEJONG MD BOUCHER CAB COOPER DA GALASSO GJ GAZZARD B LANGE JMA MONTANER JS RICHMAN DD THOMAS HC
Citation: Md. Dejong et al., SUMMARY OF THE 2ND INTERNATIONAL CONSENSUS SYMPOSIUM ON COMBINED ANTIVIRAL THERAPY AND IMPLICATIONS FOR FUTURE THERAPIES, Antiviral research, 35(2), 1997, pp. 65-82
INITIAL APPEARANCE OF THE 184ILE VARIANT IN LAMIVUDINE-TREATED PATIENTS IS CAUSED BY THE MUTATIONAL BIAS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE
Authors: KEULEN W BACK NKT VANWIJK A BOUCHER CAB BERKHOUT B
Citation: W. Keulen et al., INITIAL APPEARANCE OF THE 184ILE VARIANT IN LAMIVUDINE-TREATED PATIENTS IS CAUSED BY THE MUTATIONAL BIAS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE, Journal of virology, 71(4), 1997, pp. 3346-3350
CLINICAL-DATA SETS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE TRANSCRIPTASE-RESISTANT MUTANTS EXPLAINED BY A MATHEMATICAL-MODEL
Authors: STILIANAKIS NI BOUCHER CAB DEJONG MD VANLEEUWEN R SCHUURMAN R DEBOER RJ
Citation: Ni. Stilianakis et al., CLINICAL-DATA SETS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE TRANSCRIPTASE-RESISTANT MUTANTS EXPLAINED BY A MATHEMATICAL-MODEL, Journal of virology, 71(1), 1997, pp. 161-168
LAMIVUDINE-RESISTANT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 VARIANTS (184V) REQUIRE MULTIPLE AMINO-ACID CHANGES TO BECOME CO-RESISTANT TO ZIDOVUDINE IN-VIVO
Authors: NIJHUIS M SCHUURMAN R DEJONG D VANLEEUWEN R LANGE J DANNER S KEULEN W DEGROOT T BOUCHER CAB
Citation: M. Nijhuis et al., LAMIVUDINE-RESISTANT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 VARIANTS (184V) REQUIRE MULTIPLE AMINO-ACID CHANGES TO BECOME CO-RESISTANT TO ZIDOVUDINE IN-VIVO, The Journal of infectious diseases, 176(2), 1997, pp. 398-405
HIGH-DOSE NEVIRAPINE IN PREVIOUSLY UNTREATED HUMAN-IMMUNODEFICIENCY-VIRUS TYPE 1-INFECTED PERSONS DOES NOT RESULT IN SUSTAINED SUPPRESSION OF VIRAL REPLICATION
Authors: DEJONG MD VELLA S CARR A BOUCHER CAB IMRIE A FRENCH M HOY J SORICE S PAULUZZI S CHIODO F WEVERLING GJ VANDERENDE ME FRISSEN PJ WEIGEL HM KAUFFMANN RH LANGE JMA YOON R MORONI M HOENDERDOS E LEITZ G COOPER DA HALL D REISS P
Citation: Md. Dejong et al., HIGH-DOSE NEVIRAPINE IN PREVIOUSLY UNTREATED HUMAN-IMMUNODEFICIENCY-VIRUS TYPE 1-INFECTED PERSONS DOES NOT RESULT IN SUSTAINED SUPPRESSION OF VIRAL REPLICATION, The Journal of infectious diseases, 175(4), 1997, pp. 966-970
SELECTIVE-INHIBITION OF SYNCYTIUM-INDUCING AND NONSYNCYTIUM-INDUCING HIV-1 VARIANTS IN INDIVIDUALS RECEIVING DIDANOSINE OR ZIDOVUDINE, RESPECTIVELY
Authors: VANTWOUT AB RAN LJ DEJONG MD BAKKER M VANLEEUWEN R NOTERMANS DW LOELIGER AE DEWOLF F DANNER SA REISS P BOUCHER CAB LANGE JMA SCHUITEMAKER H
Citation: Ab. Vantwout et al., SELECTIVE-INHIBITION OF SYNCYTIUM-INDUCING AND NONSYNCYTIUM-INDUCING HIV-1 VARIANTS IN INDIVIDUALS RECEIVING DIDANOSINE OR ZIDOVUDINE, RESPECTIVELY, The Journal of clinical investigation, 100(9), 1997, pp. 2325-2332
ORDERED ACCUMULATION OF MUTATIONS IN HIV PROTEASE CONFERS RESISTANCE TO RITONAVIR
Authors: MOLLA A KORNEYEVA M GAO Q VASAVANONDA S SCHIPPER PJ MO HM MARKOWITZ M CHERNYAVSKIY T NIU P LYONS N HSU A GRANNEMAN GR HO DD BOUCHER CAB LEONARD JM NORBECK DW KEMPF DJ
Citation: A. Molla et al., ORDERED ACCUMULATION OF MUTATIONS IN HIV PROTEASE CONFERS RESISTANCE TO RITONAVIR, Nature medicine, 2(7), 1996, pp. 760-766
ANTI-CD4 THERAPY FOR AIDS SUGGESTED BY MATHEMATICAL-MODELS
Authors: DEBOER RJ BOUCHER CAB
Citation: Rj. Deboer et Cab. Boucher, ANTI-CD4 THERAPY FOR AIDS SUGGESTED BY MATHEMATICAL-MODELS, Proceedings - Royal Society. Biological Sciences, 263(1372), 1996, pp. 899-905
INDIVIDUALIZATION OF HIV THERAPY BASED ON HIV RNA LOAD - THE VIROLOGISTS PERSPECTIVE
Authors: BOUCHER CAB
Citation: Cab. Boucher, INDIVIDUALIZATION OF HIV THERAPY BASED ON HIV RNA LOAD - THE VIROLOGISTS PERSPECTIVE, International journal of antimicrobial agents, 7(3), 1996, pp. 211-215
REDUCED REPLICATION OF 3TC-RESISTANT HIV-1 VARIANTS IN PRIMARY-CELLS DUE TO A PROCESSIVITY DEFECT OF THE REVERSE-TRANSCRIPTASE ENZYME
Authors: BACK NKT NIJHUIS M KEULEN W BOUCHER CAB ESSINK BBO VANKUILENBURG ABP VANGENNIP AH BERKHOUT B
Citation: Nkt. Back et al., REDUCED REPLICATION OF 3TC-RESISTANT HIV-1 VARIANTS IN PRIMARY-CELLS DUE TO A PROCESSIVITY DEFECT OF THE REVERSE-TRANSCRIPTASE ENZYME, EMBO journal, 15(15), 1996, pp. 4040-4049
CONSENSUS SYMPOSIUM ON COMBINED ANTIVIRAL THERAPY
Authors: DEJONG MD BOUCHER CAB GALASSO GJ HIRSCH MS KERN ER LANGE JMA RICHMAN DD
Citation: Md. Dejong et al., CONSENSUS SYMPOSIUM ON COMBINED ANTIVIRAL THERAPY, Antiviral research, 29(1), 1996, pp. 5-29
MULTICENTER COMPARISON OF 3 COMMERCIAL METHODS FOR QUANTIFICATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 RNA IN PLASMA
Authors: SCHUURMAN R DESCAMPS D WEVERLING GJ KAYE S TIJNAGEL J WILLIAMS I VANLEEUWEN R TEDDER R BOUCHER CAB BRUNVEZINET F LOVEDAY C
Citation: R. Schuurman et al., MULTICENTER COMPARISON OF 3 COMMERCIAL METHODS FOR QUANTIFICATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 RNA IN PLASMA, Journal of clinical microbiology, 34(12), 1996, pp. 3016-3022
Risultati: 1-25 | 26-50 | 51-51